ArticleTransboundary and emerging diseases2026
Longitudinal Molecular Epidemiology and Genomic Evolution of Porcine Reproductive and Respiratory Syndrome Virus in a Large-Scale Swine Production System in Northern China, 2023-2026.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal Molecular Epidemiology and Genomic Evolution of Porcine Reproductive and Respiratory Syndrome Virus in a Large-Scale Swine Production System in Northern China, 2023-2026.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) remains a major threat to swine production because of its persistent circulation, genetic diversity, and frequent recombination. However, longitudinal molecular surveillance within large-scale integrated production systems remains limited. In this study, we investigated the epidemiological and genomic characteristics of PRRSV in a large-scale swine production system in Chifeng, Inner Mongolia, northern China, from January 2023 to May 2026. A total of 380,050 PRRSV nucleic acid testing records were analyzed, and 36,474 were positive, yielding an overall positivity rate of 9.60%. PRRSV detection showed marked temporal fluctuations, with increased positivity from late 2025 to early 2026, and substantial heterogeneity among farms. Nursery pigs showed the highest positivity rate among production stages, followed by finishing pigs and gilts, whereas boars had the lowest positivity. Among sample types, castration/tail-docking fluid, tongue-tip fluid, and tissue/organ samples had relatively high positivity rates. ORF5-based phylogenetic analysis revealed that all the study-derived sequences belonged to PRRSV-2, with sublineage 1.8 accounting for 53.74% and sublineage 1.5 accounting for 34.69%, indicating the predominance of lineage 1 strains. Whole-genome phylogenetic analysis of the 11 successfully assembled PRRSV genomes confirmed that they were NADC30-like PRRSVs and carried the characteristic 111 + 1 + 19 discontinuous deletion pattern in Nsp2. GP5 amino acid alignment revealed substitutions in antigenically relevant regions, including epitope A, epitope B, and predicted glycosylation-related sites. Recombination analysis revealed potential recombination events involving lineage 8-related fragments in CF-k141-31, CF-k141-560, and CF-k141-2190. These findings demonstrate that PRRSV circulation in this production system is characterized by temporal clustering, farm-level heterogeneity, lineage 1 predominance, and genomic diversification of NADC30-like strains. These results support the integration of routine real-time reverse transcription quantitative PCR (RT-qPCR) surveillance, ORF5 sequencing, and periodic whole-genome sequencing for targeted PRRSV monitoring and control in large-scale swine production systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.